The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.
Ling J , Cheng P , Ge L , Zhang DH , Shi AC , Tian JH , Chen YJ , Li XX , Zhang JY , Yang KH 
Acta Diabetol.2018 Sep 21 ; ():.
PubMedで表示
Google翻訳で開く
(146view , 0users)
The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes.
PMID: 30242726 [PubMed - as supplied by publisher]
PMID: 30242726 [PubMed - as supplied by publisher]
関連論文
- Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: A Meta-analysis.
- Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
- Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
- The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.